NextCure, Inc.
NextCure, Inc. is listed today as NextCure, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2025 | $22 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Nov 2018 | $93 M | No. 2 | $50 to $250 million | equity, options | SEC | |
| Dec 2015 | $15 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
NextCure, Inc. had no revenue when it filed its newest notice of a funding round (Dec 2025).
SEC Form D (revenue range) · Dec 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2025
Products and services#
No products or services of NextCure, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Canaan Partners X LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Canaan X L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred (Form 3, 2019) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred (Form 3, 2019) | SEC Form 3 |
| Quan Venture Fund II, L.P. | Venture capital | not stated | not stated | Held Series B-2 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Sofinnova Management IX, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Sofinnova Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 22 investors.
Largest shareholders today
Institutions holding NextCure, Inc. shares, as of Sep 30, 2026.
- ADAR1 Capital Management, LLC$4 M15.78%
- Adage Capital Partners GP, L.L.C.$2 M8.24%
- Affinity Asset Advisors, LLC$1 M6.38%
- Blackstone Inc.$1 M4.89%
- Sofinnova Investments, Inc.$1 M4.86%
- Eversept Partners, LP$1 M4.05%
- Vanguard Capital Management LLC$1 M3.43%
- Citadel Advisors LLC$1 M2.42%
- Verition Fund Management LLC$0 M2.03%
- Soleus Capital Management, L.P.$0 M1.97%
- Geode Capital Management, LLC$0 M1.71%
- Bank Of America Corp /de/$0 M1.64%
- Jpmorgan Chase & Co$0 M1.63%
- Jane Street Group, LLC$0 M1.53%
- Pfizer Inc$0 M0.97%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kevin G. Shaw | Executive officer | Dec 2025 |
| Michael Richman | Executive officer | Dec 2025 |
| Sourav G. Kundu | Executive officer | Dec 2025 |
| Steven P. Cobourn | Executive officer | Dec 2025 |
| Timothy G. Mayer | Executive officer | Dec 2025 |
| Udayan G. Guha | Executive officer | Dec 2025 |
| Kevin N. Heller | Chief Medical Officer | Nov 2018 |
| Steven Cobourn | Chief Financial Officer | Nov 2018 |
| Asher Rubin | Executive officer | Jan 2016 |
| Anne G. Borgman | Director | Dec 2025 |
| David P. Kabakoff | Director | Dec 2025 |
| Elaine V. Jones | Director | Dec 2025 |
| Ellen G. Feigal | Director | Dec 2025 |
| John G. Houston | Director | Dec 2025 |
| Michael Richman | Director | Dec 2025 |
| Stephen G. Webster | Director | Dec 2025 |
| Chau Q. Khuong | Director | Nov 2018 |
| David Kabakoff | Director | Nov 2018 |
| Elaine N. Jones | Director | Nov 2018 |
| Judith Li | Director | Nov 2018 |
| Michael Yi | Director | Nov 2018 |
| Stella Xu | Director | Nov 2018 |
| Tim Q. Shannon | Director | Nov 2018 |
| Carolyn Green | Director | Jan 2016 |
| Judith Q. Li | Director | Jan 2016 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.